Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 3
Submit an article Journal homepage
216
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

Abhishek MaitiDepartment of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA; ;Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Jorge E. CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
,
Yolanda D. BrownDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
&
Hagop M. KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Pages 722-725 | Received 29 Feb 2016, Accepted 24 Jun 2016, Published online: 23 Sep 2016

References

  • Verma D, Kantarjian H, Shan J, et al. Sustained complete molecular response to imatinib in chronic myeloid leukemia (CML): a target worth aiming and achieving? Blood. 2009;114:505.
  • Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–e193.
  • Mahon F-X, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
  • Zion M, Ben-Yehuda D, Avraham A, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 1994;91:10722–10726.
  • Issa JPJ, Kantarjian H, Mohan A, et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999;93:2075–2080.
  • Nguyen TT, Mohrbacher AF, Tsai YC, et al. Quantitative measure of c-abl andp15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000;95:2990–2992.
  • Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97:1172–1179.
  • Ge X-Q, Tanaka K, Mansyur A, et al. Possible prediction of myeloid and lymphoid crises in chronic myelocytic leukemia at onset by determining the methylation status of the major breakpoint cluster region. Cancer Genet Cytogenet. 2001;126:102–110.
  • Roman-Gomez J, Castillejo JA, Jimenez A, et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol. 2003;21:1472–1479.
  • La Rosée P, O’Dwyer M, Druker B. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (gleevec/glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia. 2002;16:1213–1219.
  • Rosée PL, Johnson K, Corbin AS, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines. Blood. 2004;103:208–215.
  • Issa JPJ, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948–3956.
  • Kantarjian HM, O’Brien S, Cortes J, et al. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98:522–528.
  • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
  • Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29:2521–2527.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.